en
Scientific article
Review
English

Loco-regional treatment in metastatic breast cancer patients: is there a survival benefit?

Published inBreast cancer research and treatment, vol. 119, no. 3, p. 537-545
Publication date2010
Abstract

A number of studies have recently demonstrated a survival benefit in stage IV breast cancer patients following surgical resection of the primary tumor. Here, we investigate the relationship between loco-regional treatment and survival in patients with metastatic breast cancer and evaluate the impact of different loco-regional treatments. We conducted a systematic review of the literature using PubMed to analyze studies with the following criteria: Type of loco-regional treatment (surgery alone or combined with radiation, radiotherapy), overall survival, progression-free survival, selection factors for local treatment, and complication rates. Thirteen studies evaluated the effect of loco-regional treatment on overall survival with overall median survival increasing from a range of 12.6-28.3 months among patients without surgery to a range of 25-42 months among patients with surgery. In addition, six studies reported a 3-year survival benefit of 28-95% and 17-79% in women with and without locoregional therapy respectively. Two studies did not find any improvement in overall survival. One study found an improvement in 5-year breast cancer-specific survival of 27% with negative surgical margins versus 12% with no surgery. Three studies reported an advantage in progression-free survival in the treatment group compared with the non-treatment group. Loco-regional treatment for breast cancer patients with distant metastases at diagnosis is an important issue because of possible improvement of survival or disease-free survival. The possibility of surgery and/or radiotherapy following induction chemotherapy should be weighed and left to individual practice. Participation in randomized controlled trials should be encouraged.

Keywords
  • Breast Neoplasms/*mortality/pathology/*therapy
  • Combined Modality Therapy
  • Disease-Free Survival
  • Female
  • Humans
  • Mastectomy
  • Neoplasm Staging
  • Radiotherapy
  • Randomized Controlled Trials as Topic
  • Risk Factors
Citation (ISO format)
LY, Bevan H. et al. Loco-regional treatment in metastatic breast cancer patients: is there a survival benefit? In: Breast cancer research and treatment, 2010, vol. 119, n° 3, p. 537–545. doi: 10.1007/s10549-009-0610-z
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0167-6806
540views
1downloads

Technical informations

Creation05/23/2012 8:50:11 AM
First validation05/23/2012 8:50:11 AM
Update time03/14/2023 5:34:14 PM
Status update03/14/2023 5:34:13 PM
Last indexation01/15/2024 11:49:35 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack